Pear Therapeutics

149 articles about Pear Therapeutics

• Pear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

  8/3/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that Cove Behavioral Health, Inc. (“Cove”) will provide access to Pear’s FDA-authorized PDT reSET-O® for the treatment of opioid use disorder (OUD).

• Pear Therapeutics to be Added to Russell US Index Series

  8/2/2022

  Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced that it will be added to the Russell US Index Series in conjunction with the September 2022 quarterly review, effective after the US market open on Monday, September 19, 2022.

• Pear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022

  7/28/2022

  Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced it will issue its second quarter 2022 financial results after the close of market on Thursday, August 11, 2022.

• Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference

  6/16/2022

  Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference.

• Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®

  6/14/2022

  Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O ® .

• Pear Presents Interim Real-World Data Showing Significant Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst® at SLEEP 2022

  6/8/2022

  Interim results from the DREAM trial showed treatment with Somryst, a prescription digital therapeutic (PDT) for patients with chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity through six months.

• Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months

  6/6/2022

  Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET ® at Six Months.

• Pear Therapeutics to Participate in the Jefferies Healthcare Conference

  6/2/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Jefferies Healthcare Conference taking place June 8-10 in New York, New York.

• Pear Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual Meeting

  5/24/2022

  Pear Announces Health Equity Data Showing Similar Engagement with reSET-O ® Across US Geographic Regions Presented at APA Annual Meeting.

• Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022

  5/19/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. – 12:30 p.m. ET.

• Pear Therapeutics Reports First Quarter 2022 Financial Results

  5/16/2022

  Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, reported financial results for its first quarter ended March 31, 2022.

• Pear Therapeutics Announces the Inclusion of QuickMD in Its Telehealth Provider Experience Initiative

  5/12/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the expansion of its program to offer patients seeking treatment for addiction access to a telehealth provider through its “find a provider tool”, along with in-person care options.

• Pear Therapeutics to Issue First Quarter 2022 Financial Results on Monday, May 16, 2022

  5/2/2022

  Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced that the company will issue its first quarter 2022 financial results after the close of market on Monday, May 16, 2022.

• Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit

  4/18/2022

  Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit.

• Pear Therapeutics Receives Safer Technologies Program (STeP) Designation from FDA for Product Candidate to Treat Acute and Chronic Pain

  4/13/2022

  Pear Therapeutics, Inc. today announced it has received Safer Technologies Program (STeP) for Medical Devices designation from the U.S. Food and Drug Administration (FDA) for Pear-010, a product candidate designed for the treatment of acute and chronic pain.

• Pear Therapeutics to Participate in Upcoming Investor Conferences - Apr 05, 2022

  4/5/2022

  Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics, announced management will participate in the following upcoming virtual investor conferences in April 2022.

• Pear Therapeutics Announces Program to Bring Prescription Digital Therapeutics to Patients in Recovery Through a Telehealth Provider Experience

  4/4/2022

  Pear Therapeutics, Inc. today announced a program to offer patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool”, along with in-person care options.

• Pear Therapeutics to Participate in Upcoming Investor Event Hosted by Credit Suisse

  3/31/2022

  Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics, announced the company will participate in the Credit Suisse The Investor Landscape: Hidden Gems Conference on Thursday, April 7 in New York, NY.

• Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

  3/28/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today reported financial results for its fourth quarter and full year 2021 ended December 31, 2021.

• Pear Therapeutics Joins Epic App Orchard to Enable Clinicians to Monitor Prescription Digital Therapeutics

  3/24/2022

  Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced its PearConnect™ platform is available to healthcare providers in the Epic App Orchard Gallery.